Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer.

ABSTRACT:

Background

Of the 200,000 U.S. men annually diagnosed with prostate cancer, approximately 20% to 30% will have clinically aggressive disease. Although factors such as Gleason score and tumor stage are used to assess prognosis, there are no biomarkers to identify men at greater risk for developing aggressive prostate cancer. We therefore undertook a search for genetic variants associated with risk of more aggressive disease.

Methods

A genome-wide scan was conducted in 202 prostate cancer cases with a more aggressive phenotype and 100 randomly sampled, age-matched prostate-specific antigen screened negative controls. Analysis of 387,384 autosomal single nucleotide polymorphisms (SNPs) was followed by validation testing in an independent set of 527 cases with more aggressive an

SUBMITTER: FitzGerald LM 

PROVIDER: S-EPMC3111761 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature